Why Indivior’s Sublocade injection is quietly changing addiction treatment

Sublocade from Indivior takes a different route in opioid use disorder treatment: one injection a month instead of daily tablets. What this long-acting buprenorphine shot means for patients, clinics, and investors.

Reviewed: ad hoc news Software & Services desk. Edited and checked on 2026-06-18, 12:22. Details in the imprint.

With Sublocade, Indivior wants opioid use disorder treatment to feel less like a daily struggle and more like a monthly reset. One injection, slow release, no pill bottles rattling in your pocket, no daily countdown until the next dose.

What Sublocade actually is

Sublocade is a once-monthly, extended-release buprenorphine injection for moderate to severe opioid use disorder that is given by a healthcare professional into the abdominal subcutaneous tissue.

The clear idea behind it is simple but powerful: instead of chasing daily tablets, patients carry a steady level of medication in their system for a full month, which helps reduce cravings and the risk of diversion.

How the monthly injection works

After injection, Sublocade forms a small depot under the skin that slowly releases buprenorphine, designed to maintain therapeutic plasma levels throughout the month.

Patients typically need to be stabilized on a daily transmucosal buprenorphine form first, then can switch to Sublocade, with the injection scheduled once every month in the clinic.

Everyday impact in the clinic

In everyday practice, the product changes the rhythm of care. Instead of queuing daily at an opioid treatment program, patients sit down once a month for a brief but focused visit and walk out without take-home medication.

For nurses and physicians, that means fewer supervised doses, less pill counting and a different conversation with patients, often more about long-term goals and less about whether they showed up for today’s dose.

Benefits that stand out

The most obvious advantage is convenience. No daily tablets means fewer missed doses and fewer opportunities to sell or share medication, a chronic problem with oral therapies in some settings.

Clinical data have shown that long-acting buprenorphine depots like Sublocade can support higher treatment retention and help patients maintain abstinence from illicit opioids compared with no medication, although outcomes vary by individual and program.

Where the limits and risks lie

The flip side is clear as well. Sublocade requires a trained professional to administer, so there is no quick switch or dose change at home if something feels off.

There are strict safety warnings: the drug must not be injected into a vein, carries a risk of serious harm if misused, and shares the usual opioid class warnings on respiratory depression and dependence.

Cost, access and market position

The list price of Sublocade in the United States is high compared with generic buprenorphine tablets, which can be a barrier for uninsured patients, although many public and private payers now include it on formularies.

Indivior positions the brand as a premium, differentiated option within a crowded addiction-treatment landscape, where the company has long experience with products such as Suboxone and now focuses heavily on injectable, long-acting formats.

Digital support and service layer

A product like Sublocade is more than a vial in the fridge. Indivior wraps it with patient support programs, reimbursement assistance and educational materials for clinicians to navigate prior authorizations and appropriate patient selection.

This service layer matters in practice, because every denied script or confused billing department can derail a treatment plan, especially in under-resourced clinics.

Indivior in the market and on the market

For Indivior, Sublocade has become a central growth driver and a cornerstone of its push into long-acting injectable treatments for addiction.

Shares of Indivior PLC (GB00BYZ0C031) trade in the US on Nasdaq under the ticker INDV, recently quoted around the high 30 dollar range according to market data.

Key facts on Sublocade at a glance

• Product: Sublocade
• Manufacturer: Indivior PLC
• Category: Software/Service/Subscription (medical treatment service)
• Launch: FDA approval in November 2017 for the US market
• RRP / Price: High four-figure US dollar range per monthly injection before discounts in the US
• Availability: Prescription-only via certified healthcare professionals, primarily in North America and selected international markets
• Target group: Adults with moderate to severe opioid use disorder seeking maintenance treatment
• Highlight / USP: Once-monthly, long-acting buprenorphine injection that reduces the need for daily dosing and lowers diversion risk

This article was AI-assisted and editorially reviewed. Product information without guarantee; prices and availability may change at short notice. No investment advice, no buy or sell recommendation. Stock-market transactions involve risks up to total loss.